31 unknown, 21 recruiting, 15 completed, 12 not yet recruiting. 88 Phase 2, 14 Phase 1, 11 Phase 3.
Follow Chemotherapy: new trials by email Literature Review of Chemotherapy trials Research Report on Chemotherapy
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Prospective, Biomarker-Stratified Phase 2 Study: β-Hydroxybutyrate as a Predictive Biomarker for Short-Course Radiotherapy Followed by Chemotherapy Plus PD-1 Inhibitor Versus Chemotherapy Alone in Locally Advanced Rectal Cancer Short-course radiotherapy, Capecitabine, Oxaliplatin - Rectal Cancer, Radiotherapy | Phase 2 | Not yet recruiting | Tao Zhang | 144 | 2026-11-01 | 2026-10-06 |
| Antibody-Drug Conjugate Plus Immunotherapy Versus Immunotherapy Plus Chemotherapy for Extensive Transurethrally Unresectable Very-High-Risk Non-Muscle-Invasive Bladder Cancer Disitamab Vedotin and Toripalimab, Toripalimab and Nab-Paclitaxel - Bladder (Urothelial, Transitional Cell) Cancer, Antibody-drug Conjugates | Phase 2 | Not yet recruiting | Tianjin Medical University Second Hospital | 150 | 2026-10-20 | 2026-10-23 |
| Iparomlimab and Tuvonralimab (QL1706) Plus Lenvatinib and Chemotherapy for Extrapulmonary Neuroendocrine Carcinoma Iparomlimab and tuvonralimab injection (QL1706) + Lenvatinib + EP/EC, EP/EC - Extrapulmonary Neuroendocrine Carcinoma (EP-NEC), QL1706 | Phase 2 | Not yet recruiting | West China Hospital | 92 | 2026-08-01 | 2026-07-31 |
| Sotagliflozin as Prevention of Anthracycline-Related Cardiotoxicity Sotagliflozin, Placebo - Anthracycline-induced Cardiotoxicity, Lymphoma | Phase 2 | Not yet recruiting | Icahn School of Medicine at Mount Sinai | 60 | 2026-07-01 | 2026-05-07 |
| Comparing of Sesame Oil, Nitroglycerin Ointment, and Aloe Vera Gel Sesame Oil, Aloe vera gel, Control - Cancer, Chemotherapy | Phase 2 | Not yet recruiting | University of Basrah | 190 | 2026-05-11 | 2026-04-28 |
| Tislelizumab Plus Chemotherapy and BACE for Unresectable NSCLC Tislelizumab, Intravenous Chemotherapy, Bronchial Artery Chemoembolization (BACE) - Unresectable Stage III Non-small Cell Lung Cancer, Tislelizumab | Phase 2 | Not yet recruiting | Sichuan Cancer Hospital and Research Institute | 39 | 2026-05-01 | 2026-05-01 |
| Prospective, Open-label, Multi-cohort Study of Becotatug Vedotin With Tislelizumab and Chemotherapy in Esophageal Squamous Cell Carcinoma - Phase 2 Tislelizumab, Becotatug Vedotin, Cisplatin - ESCC, Tislelizumab | Phase 2 | Not yet recruiting | Tianjin Medical University Cancer Institute and Hospital | 93 | 2026-04-01 | 2026-04-15 |
| A Phase 2 Randomized, Controlled Trial of QL1706 Plus Chemotherapy and Quad Shot for Driver Gene-negative Advanced Non-small Cell Lung Cancer. Quad shot, Chemotherapy, Immune Checkpoint Inhibitors - Non Small Cell Lung Cancer, Immunotherapy | Phase 2 | Not yet recruiting | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | 104 | 2026-01-30 | 2025-12-09 |
| A Pilot Study Evaluating β-hydroxybutyrate Supplementation Concomitant to Short-Course Radiotherapy Followed by Immunotherapy Combined With CAPEOX Neoadjuvant Therapy in Patients With Locally Advanced Rectal Cancer Short-course radiotherapy, Capecitabine, Oxaliplatin - Rectal Cancer, Radiotherapy | Phase 2 | Recruiting | Tao Zhang | 25 | 2026-01-01 | 2026-11-13 |
| Intestinal Low-Dose Radiotherapy Plus Immunochemotherapy for Conversion of Borderline Resectable/Unresectable Esophageal Squamous Cell Carcinoma Intestinal Low Dose Radiotherapy-1Gy, PD-1/PD-L1 inhibitors, Chemotherapy - Borderline Resectable Carcinoma, Unresectable Cancer | Phase 2 | Recruiting | Chuangzhen Chen | 39 | 2025-12-05 | 2026-10-05 |
| Entinostat & Chemotherapy for Locally Advanced or Metastatic Bladder Cancer Entinostat, Chemotherapy - Bladder Cancer, Histone Deacetylase Inhibitor | Phase 1 / Phase 2 | Not yet recruiting | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | 29 | 2025-12-01 | 2025-12-03 |
| Targeted Induction Therapy for Stage III Unresectable EGFR Mutant Positive NSCLC Fumetinib combined platinum-based double chemotherapy, Concurrent Radiochemotherapy - EGFR, NSCLC (Non-small Cell Lung Cancer) | Phase 2 | Recruiting | Peng Zhang | 160 | 2025-11-25 | 2026-08-03 |
| Hypofractionated Radiotherapy Combined With Immunochemotherapy for Conversion Treatment of Gastroesophageal Junction Adenocarcinoma hypofractionated radiotherapy, SOX Chemotherapy, PD-1 inhibitor - Gastroesophageal Junction Adenocarcinoma, Hypofractionated Radiotherapy | Phase 1 / Phase 2 | Recruiting | West China Hospital | 88 | 2025-09-15 | 2025-11-28 |
| Adebrelimab + Chemotherapy as Neoadjuvant Therapy for Resectable NSCLC Adebrelimab, chemotherapy - Adebrelimab (SHR-1316), NSCLC | Phase 2 | Not yet recruiting | Zhangzhou Municipal Hospital | 32 | 2025-06-20 | 2025-06-25 |
| A Randomized Controlled Trial of Plasma ctDNA Methylation-Guided Adjuvant Chemotherapy Decision-Making in High-Risk Stage III (T4N+ or T1-3N2) Colorectal Cancer FOLFOX, Folfox plus Bevacizumab - ctDNA, Chemotherapy | Phase 2 | Recruiting | Fudan University | 100 | 2025-04-01 | 2026-05-01 |
| Total Neoadjuvant FLOT Chemotherapy in Locally Advanced Gastric and Gastroesophageal Junction Cancer Docetaxel, Oxaliplatin, Leucovorin - Gastric Cancer, Stomach Cancer | Phase 2 / Phase 3 | Recruiting | Ukrainian Society of Clinical Oncology | 150 | 2025-03-25 | 2025-05-06 |
| Two-cycle and Three-cycle Induction Therapy With Modified TPF Regimen Combined and Camrelizumab for LANPC Two-cycle induction chemotherapy + immunotherapy, Three-cycle induction chemotherapy + immunotherapy - Nasopharyngeal Neoplasms, PD-1 Inhibitor | Phase 2 | Recruiting | The First Affiliated Hospital of Xiamen University | 208 | 2025-02-25 | 2025-07-01 |
| Assessment of Adebelizumab Combined With Chemotherapy in Concurrent Radiotherapy Versus Sequential Radiotherapy as First-Line Treatment for Extensive-Stage Small Cell Lung Cancer First-line Immunotherapy Combined with Chemoradiotherapy for ES-SCLC - SCLC, Extensive Stage, Immunotherapy | Phase 2 | Recruiting | Peking University Cancer Hospital & Institute | 60 | 2025-01-07 | 2026-08-17 |
| Total Neoadjuvant Therapy and Organ Preservation Versus Surgery for Rectal Cancer. Radiation Therapy, Chemoradiotherapy, Consolidation Chemotherapy - Rectal Cancer, Total Neoadjuvant Treatment | Phase 2 / Phase 3 | Recruiting | National Cancer Center Affiliate of Vilnius University Hospital Santaros Klinikos | 400 | 2025-01-06 | 2026-05-11 |
| Oral Chemotherapy, Targeted Therapy and Immunotherapy With/Without Radiotherapy as 3rd- or Later-line Therapy for Advanced MSS/pMMR Colorectal Cancer Trifluorouracil tepidopyrimidine, Bevacizumab, Sindilizumab - Colorectal Cancer Metastatic, Chemotherapy | Phase 2 | Recruiting | Sun Yat-sen University | 57 | 2024-12-31 | 2025-08-24 |
Showing 20 of 88. Sign in to see all of them.
Colorectal Neoplasms (9) · Neoplasms (9) · Uterine Cervical Neoplasms (6) · Breast Neoplasms (5) · Carcinoma, Non-Small-Cell Lung (4) · Esophageal Neoplasms (4) · Neoplasm Metastasis (4) · Nausea (3) · Neutropenia (3) · Rectal Neoplasms (3) · Stomach Neoplasms (3) · Vomiting (3) · Anemia (2) · Esophageal Squamous Cell Carcinoma (2) · Fatigue (2)
Neoplasms (56) · Neoplasms by Site (49) · Digestive System Diseases (23) · Digestive System Neoplasms (23) · Gastrointestinal Diseases (22) · Gastrointestinal Neoplasms (21) · Pathological Conditions, Signs and Symptoms (16) · Intestinal Diseases (13) · Intestinal Neoplasms (13) · Neoplasms by Histologic Type (12) · Rectal Diseases (12) · Colonic Diseases (11) · Head and Neck Neoplasms (11) · Hemic and Lymphatic Diseases (11) · Pathologic Processes (11)
Drug Therapy (14) · Cisplatin (8) · Oxaliplatin (7) · Capecitabine (6) · Docetaxel (6) · Fluorouracil (6) · Chemoradiotherapy (5) · Bevacizumab (4) · Folfox protocol (4) · Immune Checkpoint Inhibitors (4) · Surgical Procedures, Operative (4) · toripalimab (4) · Albumin-Bound Paclitaxel (3) · Carboplatin (3) · Cyclophosphamide (3)
Fudan University (6) · Lei Li (6) · Sun Yat-sen University (3) · Cancer Institute and Hospital, Chinese Academy of Medical Sciences (2) · Harbin Medical University (2) · Henan Cancer Hospital (2) · Johnson & Johnson Pharmaceutical Research & Development, L.L.C. (2) · Ningbo Cancer Hospital (2) · Shanghai International Medical Center (2) · Tang-Du Hospital (2) · Tao Zhang (2) · The First Affiliated Hospital of Xiamen University (2) · Union Hospital, Tongji Medical College, Huazhong University of Science and Technology (2) · West China Hospital (2) · Zibo Municipal Hospital (2)
China (52) · France (5) · United States (5) · Taiwan (3) · Israel (2) · Italy (2) · Lithuania (2) · Belgium (1) · Brazil (1) · Canada (1) · Egypt (1) · Iran (1) · Netherlands (1) · Puerto Rico (1) · Russia (1)
Lei Li, M.D. (6) · Huajun Jin (2) · Jiangtao Wang (2) · Qijun Qian (2) · Xiaonan Hong, MD (2) · Zhenyu Lin (2) · Audrius Dulskas, PhD (1) · Brad Willcox, MD (1) · Carlos G Santos-Gallego, MD (1) · Catherine Thieblemont, MD (1) · Charles E. Matthews, PhD (1)
PMID 11230497, PMID 11481354, PMID 11489791, PMID 11895891, PMID 16133789, PMID 16271446, PMID 1651156, PMID 17468871, PMID 17954800, PMID 19349540, PMID 19425235, PMID 19826112, PMID 20049561, PMID 20622770, PMID 21218740, PMID 21471870, PMID 22211087, PMID 22811849, PMID 23372097, PMID 23406728, PMID 23563998, PMID 23880820, PMID 23955585, PMID 24373830, PMID 25577133, PMID 26036623, PMID 26512574, PMID 26615328, PMID 27091418, PMID 27871319, PMID 30207593, PMID 31453801, PMID 32045142, PMID 32150833, PMID 32702383, PMID 35574368, PMID 36158690, PMID 36872649, PMID 38418234, PMID 39465257, PMID 40468090, PMID 41499358
2016 (2)